Skip to main content

Table 1 Mean (standard deviation) values at baseline and 12 months after the Can Do treatment with relative difference (percentage of baseline) (mean, standard error of the mean) and P value for comparison (paired t-test) for self-efficacy [multiple sclerosis self-efficacy scale (MSSES)], impact on participation and autonomy [impact on participation and autonomy questionnaire (IPA)], HRQoL [multiple sclerosis quality of life-54 Items (MSQoL-54)], anxiety and depression [Hospital anxiety and depression scale (HADS)], and fatigue [modified fatigue impact scale-5 items (MFIS-5)] in the relapsing remitting group (N = 22); Δ, difference

From: Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later

Relapsing remitting group Baseline 12th month % Δ P
MSSES function (N = 21) 80.86 (15.00) 79.58 (16.24) −0.68 (3.00) 0.708
MSSES control (N = 21) 57.68 (19.29) 64.02 (15.81) +20.21 (7.83) 0.012
IPA limitations (N = 22) 2.40 (0.60) 2.28 (0.60) −0.53 (7.41) 0.356
IPA problems (N = 20) 1.97 (0.37) 1.75 (0.51) −8.38 (5.51) 0.075
MSQoL-54 physical (N = 11) 56.87 (11.93) 59.85 (18.68) +14.99 (7.09) 0.032
MSQoL-54 mental (N = 17) 55.98 (11.82) 63.47 (14.12) +17.38 (8.16) 0.087
HADS anxiety (N = 22) 7.23 (3.45) 5.50 (3.16) −25.89 (8.64) 0.044
HADS depression (N = 22) 5.59 (3.62) 3.86 (3.23) −29.76 (14.53) 0.042
MFIS-5 (N = 22) 12.09 (3.95) 9.95 (3.77) −19.82 (7.34) 0.080